Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.
Pfizer’s attempt to secure an Arrow declaration in relation to its proposed launch of a cancer drug in Europe was shot down yesterday, June 20, by the English High Court.
US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.
British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.
BASF Plant Science, the plant biotech-focused subsidiary of BASF, has asked the US Court of Appeals for the Federal Circuit to overturn a finding that certain claims of a transgenic plant technology patent were invalid.
A Russian scientist is planning to create CRISPR-edited babies, despite the widespread condemnation levelled at the first scientist who created ‘edited’ twins.
Dominican Republic-based Agroindustrial Ocoeña has asked a US court to dismiss its plant patent claim against a competitor run by the patent inventor’s brother.
US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.
The US International Trade Commission has issued a judgment after a surgical appliances company, Polymer Technology Systems (PTS), filed a complaint against a China-based competitor.
American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.